Plus Therapeutics announced that it will present three sets of positive clinical data for its lead radiotherapeutic candidate REYOBIQ at the World Federation of Neuro‑Oncology Societies/Society for Neuro‑Oncology (WFNOS/SNO) Annual Meeting, which ran from November 19‑23 2025 in Honolulu, Hawaii.
The first presentation will cover Cohort 1 of the Phase 1 multiple‑dose ReSPECT‑LM trial. The data show no dose‑limiting toxicity at the starting dose of 13.2 mCi, and the trial is proceeding to the next dose level with a recommended Phase 2 dose of 22.3 mCi.
The second presentation will focus on early safety and efficacy signals from the ReSPECT‑GBM trial in recurrent glioblastoma. The trial has enrolled 34 patients, with 24 already receiving the recommended Phase 2 dose, and the interim analysis indicates a manageable safety profile and encouraging signs of tumor response.
The third presentation will report imaging biomarker results that combine MRI and SPECT to assess response. Median overall survival was 17 months for patients receiving ≥100 Gy versus 6 months for those receiving <100 Gy, underscoring the potential therapeutic benefit of REYOBIQ in both indications.
CEO Marc H. Hedrick said the data “continue to demonstrate a favorable safety profile and encouraging signs of efficacy, giving us growing confidence that we can achieve our goal of materially improving survival rates for patients with CNS cancers.” He added that the company will use the FDA meeting minutes to refine the LM trial and accelerate the overall development timeline.
The presentations reinforce the company’s strategy to advance REYOBIQ through Phase 2 enrollment and to prepare for future regulatory submissions. The data also support the company’s broader clinical development plan and its diagnostic platform, CNSide, while the company’s recent grant funding and ongoing FDA engagement provide a solid foundation for continued progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.